ZURICH, July 19 (Reuters) - Roche's Japanese subsidiary Chugai said on Tuesday subcutaneous injection of its Actemra drug has shown efficacy in rheumatoid arthritis compared to intravenous infusion.
Subcutaneous tocilizumab, alone or with methotrexate, showed superior efficacy over methotrexate monotherapy in treating rheumatoid arthritis in Chinese patients. The trial demonstrated higher ACR20 ...
Credit: Fresenius Kabi. Tyenne is indicated for treatment of moderately to severely active rheumatoid arthritis, giant cell arteritis, active polyarticular juvenile idiopathic arthritis, and active ...
The FDA has approved the first biosimilar version of the interleukin-6 (IL-6) blocker tocilizumab, to be marketed as Tofidence and with indications for rheumatoid arthritis (RA), systemic juvenile ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Actemra ...
Please provide your email address to receive an email when new articles are posted on . Tyenne (tocilizumab-aazg) is available in a prefilled syringe, pen injector or vial. The biosimilar will launch ...
Subcutaneous (subQ or SQ) injections are shots given in the fatty tissue layer (subcutaneous fat) under your skin. Your skin has many layers, and the subcutaneous layer is beneath the epidermis and ...